Indications
Palimax ER 3 Tablet is used for:
Schizophrenia, Schizoaffective Disorder
Adult Dose
Oral
Schizophrenia
Adult: Initially, 6 mg once daily in the morning.
May be titrated upward or downward in increments of 3 mg/day at intervals >5 days; not to exceed 12 mg/day
Schizoaffective Disorder
Indicated for schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants
6 mg PO qDay in am (range 3-12 mg); titration may not be necessary; if exceeding 6 mg/day, increases of 3 mg/day recommended at intervals of 4 days of more; not to exceed 12 mg/day
Child Dose
Schizophrenia
<12 years: Safety and efficacy not established
>12 years (<51 kg): 3 mg/day PO initially; may be increased if necessary in increments of 3 mg/day at intervals ?5 days; not to exceed 6 mg/day
>12 years (>51 kg): 3 mg/day PO initially; may be increased if necessary in increments of 3 mg/day at intervals ?5 days; not to exceed 12 mg/day
Schizoaffective Disorder
<18 years: Safety and efficacy not established
Renal Dose
Renal impairment
CrCl 50-79 mL/min: 3 mg/day initially; not to exceed 6 mg/day
CrCl 10-49 mL/min: 1.5 mg/day initially; not to exceed 3 mg/day
CrCl <10 mL/min: Not recommended
Administration
May be taken with or without food
Contra Indications
Hypersensitivity to paliperidone or risperidone.
Precautions
Patient w/ known CV disease or family history of QT prolongation, history of seizures or other conditions that potentially lower the seizure threshold, predisposition to GI obstruction, possible prolactin-dependent tumours, Parkinson's disease. Cataract surgery. Elderly w/ dementia-related psychosis and risk factors for stroke. Renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and impairment of judgment, thinking or motor skills, if affected, avoid driving, operating machinery or performing hazardous tasks. Monitoring Parameters Monitor mental status changes, vital signs, wt, BP, electrolyte, renal and hepatic function. Closely monitor for worsening glucose control in patients w/ pre-existing DM.
Lactation: Drug excreted in breast milk; do not nurse
Pregnancy-Lactation
Pregnancy
There are no adequate and well controlled studies in pregnant women; use of first generation antipsychotic drugs during last trimester of pregnancy associated with extrapyramidal symptoms in neonate; symptoms are usually self-limited; not known whether paliperidone, when taken near end of pregnancy, will lead to similar neonatal signs and symptoms; in animal reproduction studies, there were no increases in fetal abnormalities when pregnant rats and rabbits were treated during the period of organogenesis with up to 8 times the maximum recommended human dose of paliperidone (on a mg/m² basis); in rat reproduction studies with risperidone, which is extensively converted to paliperidone in rats and humans, there were increases in pup deaths seen at oral doses which are less than maximum recommended human dose of risperidone on a mg/m² basis
Infertility
Based on pharmacologic action of paliperidone (D2 receptor antagonism), treatment may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential
Lactation
Limited data from published literature report presence of paliperidone in human breast milk; there is no information on effects on breastfed infant, or on milk production; however, there are reports of sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements) in breastfed infants exposed to paliperidone’s parent compound, risperidone; consider developmental and health benefits of breastfeeding along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from mother’s underlying condition
Infants exposed to treatment through breastmilk should be monitored for excess sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements)
Interactions
Increased risk of QT prolongation w/ class IA (e.g. quinidine, disopyramide) and class III (e.g. amiodarone, sotalol) antiarrhythmics. Additive effects w/ drugs that cause orthostatic hypotension (e.g. other antipsychotics, tricyclics). May antagonise actions of levodopa and other dopaminergics. Additive effect w/ drugs known to lower seizure threshold (e.g. phenothiazines or butyrophenones, clozapine, tricyclics or SSRIs, tramadol, mefloquine). May reduce plasma levels w/ carbamazepine. Enhanced central effects w/ other CNS depressants. May increase plasma levels w/ valproate. May affect the absorption w/ metoclopramide.
Side Effects
Side effects of Paliperidone :
>10%
Akathisia, Somnolence, Insomnia, Parkinsonism, Tachycardia, Hyperprolactinemia, Others similar to placebo (eg, headache)
<10% (selected)
Cough, Dystonia, Extrapyramidal symptoms (EPS), Orthostatic hypotension, QT prolongation, Sialorrhea, Priapism, Weight gain, Constipation, Indigestion, Amenorrhea, Galactorrhea, Nausea, Dyspepsia, Salivation, Xerostomia, Myalgia, Extremity pain, Nasopharyngitis
Mode of Action
Major metabolite of risperidone; improves negative symptoms of psychoses and reduces incidence of EPS
Has high affinity for serotonin type 2 (5-HT2) receptors; binds to dopamine D2 receptors with 20 times lower affinity than that for 5-HT2 receptors; antagonizes alpha1-adrenergic, alpha2-adrenergic, and histaminergic receptors; has moderate affinity for serotonin type 1 (5-HT1C, 5-HT1D, 5-HT1A) receptors; has weak affinity for dopamine D1 receptors; has no affinity for muscarinic, beta1-adrenergic, and beta2-adrenergic receptors
Note
Palimax ER 3 3mg Tablet generic name is Paliperidone. Palimax ER 3 3mg Tablet is manufactured by ACI LimitedPalimax ER 3 is availble in all over Bangladesh.
Mes BD drug index information on Palimax ER 3 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Paliperidone :
Tablet
Palimax ER 1.5
1.5mg
ACI Limited
Tablet
Palimax ER 6
6mg
ACI Limited
Injection
Invega Sustenna
75mg
Marketed By Unimed & Unihealth Manufacturers Ltd (Janssen-Cilag Products)
Injection
Invega Sustenna
100mg
Marketed By Unimed & Unihealth Manufacturers Ltd (Janssen-Cilag Products)
Injection
Invega Sustenna
150mg
Marketed By Unimed & Unihealth Manufacturers Ltd (Janssen-Cilag Products)